Sylvester Researchers study QoL During Immunotherapy Treatment
Sylvester Comprehensive Cancer Center shared a post on X:
“With a $5.2M grant from the National Cancer Institute, Dr. Moreno, Dr. Jose Lutzky, and Dr. Gilberto Lopes will track side effects over two years, using machine learning to identify patients at higher risk. Their findings could help personalize treatment and improve patient care. Learn more.”
Gilberto Lopes, Medical Director for international programs and associate director at the Sylvester Comprehensive Cancer Center, shared this post, adding:
“Proud of Dr. Moreno’s and our team’s work in improving the quality of life of immunotherapies as in this newly awarded grant and targeted therapies as in results of SkippIRR showing that desamethansone decreases infusion reactions with amivantamab. More to come!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023